Drugs / CM3.1-AC100
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01196728 | Sep → Nov 2010 | type 2 diabetes mellitus | CellMed AG, a subsidiary of BTG plc. | Completed | No outcome recorded |
| Phase 1 | NCT01165502 | Jul → Nov 2010 | — | CellMed AG, a subsidiary of BTG plc. | Completed | No outcome recorded |
| Phase 1 | NCT01028521 | Feb → May 2010 | — | CellMed AG, a subsidiary of BTG plc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CM3.1-AC100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01165502 ↗ |
| Modality | Peptide | “GLP-1 peptide analogue” NCT01165502 ↗ |
| Route | Subcutaneous | “Solution for sc injection” NCT01028521 ↗ |